Cetera Investment Advisers
HRMY icon

Cetera Investment Advisers’s Harmony Biosciences HRMY Stock Holding History

Cetera Investment Advisers’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,196
Closed -$344K – 4874
2025
Q4 		$344K Buy
9,196
+850
+10% +$27.9K ﹤0.01% 3775
2025
Q3 		$230K Sell
8,346
-58
-0.7% -$2K ﹤0.01% 4054
2025
Q2 		$266K Buy
8,404
+748
+10% +$24.1K ﹤0.01% 3497
2025
Q1 		$254K Buy
7,656
+754
+11% +$27K ﹤0.01% 3410
2024
Q4 		$237K Sell
6,902
-46
-0.7% -$1.58K ﹤0.01% 3291
2024
Q3 		$278K Sell
6,948
-536
-7% -$18.8K ﹤0.01% 3130
2024
Q2 		$226K Sell
7,484
-1,523
-17% -$45.8K ﹤0.01% 3284
2024
Q1 		$302K Buy
+9,007
New +$289K ﹤0.01% 3033

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Cetera Investment Advisers's HRMY Position: Q1 2026 in Review

Cetera Investment Advisers sold out of Harmony Biosciences (HRMY) in Q1 2026, closing a stake of 9,196 shares — an estimated $344K sold.

Cetera Investment Advisers first reported a position in HRMY in Q1 2024 and held it in 8 quarters. The position peaked at $344K in Q4 2025. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • Cetera Investment Advisers reported no remaining Harmony Biosciences position as of Q1 2026 after selling out during the quarter.
  • Cetera Investment Advisers sold 9,196 Harmony Biosciences shares in Q1 2026, an estimated $344K.
  • Cetera Investment Advisers first reported a position in Harmony Biosciences in Q1 2024 and held it in 8 quarters.
  • Cetera Investment Advisers's Harmony Biosciences position peaked at $344K in Q4 2025.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.